The stock of Royalty Pharma plc (NASDAQ:RPRX) increased by $0.34 on Tuesday to finish at $30.73, up 1.12 percent. The last five days have seen an average of 2,213,660 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$8.79. The average number of shares traded over the last 20 days was 2,055,700, while the average volume over the last 50 days totaled 2,153,824.
RPRX stock dropped -2.07% since last month. On 08/18/23, the company’s shares reached a one-month low of $28.98. The stock touched a high of $44.47 on 01/03/23, after rallying from a low of $28.98 in 52 weeks. The price of RPRX stock has declined by -22.24% or -$8.79 this year, reaching a new high 1 time. Still, the stock price is down -30.90% from the 52-week high.
Insider Transactions
RPRX stock investors should be aware that Royalty Pharma plc (RPRX) stock had its last reported insider trading activity 20 days ago on Aug 10. On Aug 10, EVP & CFO Coyne Terrance P. sold 37,500 shares at $30.75 each. This transaction resulted in the insider making $1,153,091. On Aug 09, Coyne Terrance P. sold 37,500 shares at a price of US$30.72. After the transaction, the insider now owns 827,500 shares. EVP & CFO Coyne Terrance P. had earlier sold 37,500 shares on Jul 13 for $30.93 a share. The transaction was completed for $1,159,958.
Valuation Metrics
Royalty Pharma plc (RPRX) has a trailing price-to-earnings (P/E) ratio of 54.68. Beta for the stock is 0.39. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 7.66, the price-to-book (PB) ratio of 2.20, and the price-to-cash flow ratio of 34.69.
Company paid $0.20 per share in dividends, remained unchanged from $0.20 last year. A $0.01 dividend increase was reported on Monday January 9 2023.
Financial Health
For the three months ended June 29, Royalty Pharma plc’s quick ratio was 2.50, while its current ratio was 2.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.98, and the total debt to equity ratio is 1.13. Royalty Pharma plc’s operating margin stood at 18.50% for the same period. Based on annual data, it had gross profit of $1.93 billion and revenue of $2.24 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. RPRX’s return on assets (ROA) during the last 12 months has been 1.50%. There was a 2.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 4.20%.
Earnings Surprise
According to Royalty Pharma plc’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $538.2 million, while revenues rose by 0.42% to $683.97 million. It was predicted that Royalty Pharma plc’s quarterly earnings would be $0.84, but it ended up being $0.81, beating the consensus by 3.70%. EBITDA was $254.16 million for the quarter. At the end of Royalty Pharma plc’s most recent quarter ended June 29, its liabilities totaled 7.31 billion, while its total debt was $7.13 billion. Equity owned by shareholders amounts to $601.82 million.
Technical Picture
Here’s a quick look at Royalty Pharma plc’s (RPRX) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 65.91%, suggesting the stock is Neutral, with a 15.39% historical volatility rate.
The stochastic %K and %D were 63.79% and 47.44% respectively, while the average true range (ATR) was 0.60. Based on the 14-day stochastic reading of 82.98%, the RSI (14) reading is 57.03%. On the 9-day MACD Oscillator, the stock is at 0.62, and the 14-day reading is at 0.51.
Analyst Ratings
Analysts have assigned Royalty Pharma plc (RPRX) an Buy rating. RPRX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.
What is RPRX’s price target for the next 12 months?
The current consensus forecast for the stock is between $40.00 and $60.00, with a median target price of $48.90. In analyzing these forecasts, the average price target given by analysts for Royalty Pharma plc (RPRX) is $48.35.
